Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 629

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1C
Chunk 629
---
000(3) 
    $5.02(4) 
    $5.26  
    $782,000 
  
    Christopher Chapman, former
    CEO 
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     - 
  
    Nathen Fuentes, former CFO 
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     - 

(1)
The “Grant Date” represents the date on which the Compensation Committee of the Board took action to grant the applicable
award

(2)
The stock awards disclosed in this item consist of options, as issued under our 2023 Omnibus Incentive Plan, which vest 50% at grant
date, and 50% six months from grant date.

(3)The
stock awards disclosed in this item consist of options, as issued under our 2023 Omnibus Incentive Plan, which vest ratably in fourths
every six months beginning February 2024

(4)
The Compensation Committee granted these stock awards using the closing price on 8/26/2024 of $5.02 as the basis for the award.

Retirement
Plans

We
do not currently maintain any retirement plans for our employees.

63

Outstanding
Equity Awards at Fiscal Year-End

The
following table summarizes outstanding unexercised options held by each of the named executive officers, as of December 31, 2024:

    Name 
    Number
    of Securities Underlying Unexercised Options (#) Exercisable  
    Number
    of Securities Underlying Unexercised Options (#) Unexercisable  
    Equity
    Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options 
(#)  
    Options
    Exercise Prices ($)  
    Option
    Expiration Date 
    Number
    of Shares or Units of Stock That Have Not Vested (#)  
    Market
    Value of Shares or Units of Stock That Have Not Vested ($)  
    Equity